MESO Latest Press Releases

-- November 4, 2026 --

Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar Globe Newswire 7:11 PM

-- November 1, 2026 --

Mesoblast Board Changes Globe Newswire 6:46 PM

-- October 28, 2026 --

Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) Globe Newswire 8:19 PM

-- September 24, 2026 --

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product Globe Newswire 7:00 AM

-- August 26, 2026 --

Mesoblast Reports Substantial Revenue Growth to US$120M Globe Newswire 8:32 PM

-- August 24, 2026 --

Mesoblast Financial Results and Corporate Update Webcast Globe Newswire 7:00 AM

-- August 16, 2026 --

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain Globe Newswire 8:35 PM

-- July 29, 2026 --

Mesoblast Reports Ryoncil Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch Globe Newswire 8:57 PM

-- July 13, 2026 --

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain Globe Newswire 8:35 PM

-- July 9, 2026 --

Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 Globe Newswire 8:30 PM

-- June 30, 2026 --

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs Globe Newswire 8:38 PM

-- June 24, 2026 --

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility Globe Newswire 8:59 PM

Market Data Delayed 15 Minutes